Yaz Lawsuit

Yaz is a birth control pill made by Bayer HealthCare Pharmaceuticals. Based in Germany, Bayer HealthCare Pharmaceuticals is one of the world’s top pharmaceutical companies. Yaz hit the U.S. market in 2006. Similar drugs Yasmin and Ocella have also been under scrutiny. Yasmin is also manufactured by Bayer. It is the lower-dose version of Yaz. Ocella is a generic version of the active ingredient drospirenone. Ocella is marketed by Teva Pharmaceuticals and manufactured by Barr Laboratories.

While these birth control drugs have been effective for millions of women, many have also suffered serious health complications. Thousands of women have filed Yasmin and Yaz lawsuits against Bayer to receive financial compensation. While the numbers continue to grow, Bayer faces more than 13,600 Yasmin and Yaz lawsuits. Additional Yasmin and Yaz lawsuits are being filed in Europe.

Yaz Complications

Reports in the British Medical Journal revealed a twofold to threefold increased risk of developing blood clots when women took drospirenone pills like Yaz. Research shows that drospirenone can cause hyperkalemia. Hyperkalemia is an increase the body’s potassium levels. This can in turn create severe health complications.

Yaz users have experienced life-threatening complications, including:

  • Heart attacks
  • Strokes
  • Gallbladder disease
  • Deep vein thrombosis, or blood clots in deep veins such as the leg or thigh
  • Pulmonary embolism, or blockage of the lung’s main artery

Yaz Marketing Controversy

When marketing Yaz, Bayer is accused of overstating the efficacy of the drug. Yaz advertisements claimed that it could also be used to treat hormonal issues such as PMS and all forms of acne. In reality, the FDA approved Yaz only for moderate forms of acne and premenstrual dysphoric disorder, or PMDD. PMDD is a severe and rarer form of PMS.

Additionally, the FDA noted that Yaz advertisements failed to adequately inform consumers of the risks of treatment. The Yaz commercial featured rapid scene changes and background music. These elements distracted from the part of the commercial that outlined Yaz’s risks and side effects. The FDA required that Bayer discontinue these commercials. Additionally, Bayer was required to stress the risk of blood clots on packaging for Yasmin and yaz.

Yaz Lawsuit Status

Bayer has agreed to pay $1 billion to settle Yasmin and Yaz lawsuit claims for women who developed blood clots. More than 4,800 women participated in this Yasmin and Yaz lawsuit. As a result, these Yasmin and Yaz lawsuit plaintiffs suffered strokes, heart attacks, and other life-threatening complications. More than 100 deaths have been reported among users. While the $1 billion settlement appears costly, Bayer reported $51 billion in sales revenue in 2012. Surprisingly, Bayer stock value reached an all-time high in 2012.

In early 2013, Bayer agreed to pay a lump settlement of $24 million to all Yaz and Yasmin users who developed gallbladder disease. While the total is currently unknown, it is estimated that roughly 8,000 women will be involved in the settlement. This could result in $2,000 to $3,000 for each plaintiff. The settlement is significantly lower for patients who suffered blood clots and cardiovascular complications. This is because the gallbladder is not considered a vital organ for bodily function.

Filing a Yaz Lawsuit

Those who wish to file a lawsuit should speak with an attorney immediately. There is a certain window of time to file a Yasmin or Yaz lawsuit claim. An experienced attorney can help evaluate each case and discuss the optimal legal options. Those who have suffered life-threatening complications may be entitled to receive financial compensation for medical bills, lost wages, pain, and suffering. Additionally, those who have lost a loved one may be entitled to compensation for their loss.

Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA. 

View Sources


  • “Drospirenone safety alert.” MPR [Obstetrician & Gynecologist Edition] Spring-Summer 2012: A-7(1). Academic OneFile. Web. 25 Mar. 2013.
  • “FDA updates drospirenone-containing birth control pill labels to emphasize possible increased risk of blood clots in women.”Formulary May 2012: 179. Academic OneFile. Web. 25 Mar. 2013.
  • Kresge, Naomi. “Bayer Sees 2013 Sales Growth on Drugs, Crop Chemicals.” Bloomberg. Bloomberg, 28 Feb 2013. Web. 25 Mar 2013. https://www.bloomberg.com/news/2013-02-28/bayer-sees-2013-sales-growth-on-drugs-crop-chemicals.html
  • Thomas, Steve. “Bayer continues to brace for Yaz lawsuits.”The Legal Examiner Houston. The Legal Examiner, 18 Mar 2013. Web. 25 Mar 2013.
  • “U.S. orders review of risks of some birth control pills.” New York Times 1 June 2011: B5(L). Academic OneFile. Web. 25 Mar. 2013.
  • “Women sue Bayer over Yasmin birth control pills.” Adverse Event Reporting News 9 Feb. 2010: 16. Academic OneFile. Web. 25 Mar. 2013.